This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Miguel Gracia-Guzman Blanco: Innovator in Muscarinic Receptor Modulation
Introduction
Miguel Gracia-Guzman Blanco is a notable inventor based in San Diego, California. He has made significant contributions to the field of pharmacology through his innovative work on muscarinic receptors. With one patent to his name, his research is focused on developing novel compounds that can modulate these receptors effectively.
Latest Patents
Miguel's patent titled "Modulators of Muscarinic Receptors" pertains to substituted piperazine compounds. This invention introduces compounds that serve as useful modulators of muscarinic receptors. Additionally, the patent provides valuable compositions that incorporate these compounds and delineates methods for treating diseases mediated by muscarinic receptors. This research holds promise for enhancing therapeutic approaches to related medical conditions.
Career Highlights
Miguel Gracia-Guzman Blanco is currently employed at Vertex Pharmaceuticals, Inc., where he leverages his expertise in pharmaceutical sciences. His work focuses on advancing the understanding and treatment of diseases that involve muscarinic receptors. His contributions to Vertex have been instrumental in progressing the company's research initiatives within this field.
Collaborations
Throughout his professional journey, Miguel has collaborated with esteemed colleagues including Lewis R. Makings and Dennis James Hurley. These collaborations have allowed for the pooling of ideas and expertise, furthering advancements in research related to muscarinic receptors and their modulators.
Conclusion
In summary, Miguel Gracia-Guzman Blanco exemplifies innovation in pharmacological research, particularly in the modulation of muscarinic receptors. His patent underscores his commitment to developing effective therapeutic solutions and highlights the collaborative efforts with his peers in the field. As he continues his work at Vertex Pharmaceuticals, his contributions are set to impact the landscape of treatment for muscarinic receptor mediated diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile